The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback